These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 3991030)

  • 1. [Bioavailability of a delayed-action aminophylline preparation].
    Regazzi MB; Guarnone E; Bartoli A; Ciardelli L; Piacentini P
    Minerva Med; 1985 Mar; 76(13):641-5. PubMed ID: 3991030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing.
    Schulz HU; Steinijans VW; Gabel H
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):621-5. PubMed ID: 6500759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of a new sustained-release theophylline preparation.
    Dahlqvist R; Billing B
    Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):69-72. PubMed ID: 6840927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absolute bioavailability of a new pediatric sustained release theophylline tablet, when given as whole or divided tablets.
    Jonkman JH; van der Boon WJ; Schoenmaker R; Holtkamp A; Thürkow-Luikens AJ
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):506-10. PubMed ID: 6500770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bioavailability of theophylline after oral administration of a retard preparation of theophylline-ethylenediamine and the influence of 15-day ingestion on elimination kinetics after i.v. injection (author's transl)].
    Wiessmann KJ
    Arzneimittelforschung; 1980; 30(2):329-32. PubMed ID: 7378114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of enteral feedings on sustained-release theophylline absorption.
    Plezia PM; Thornley SM; Kramer TH; Armstrong EP
    Pharmacotherapy; 1990; 10(5):356-61. PubMed ID: 2122422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the absorption from three ibuprofen formulations.
    Regazzi BM; Rondanelli R; Ciaroelli L; Bartoli AL; Rampini A
    Int J Clin Pharmacol Res; 1986; 6(6):469-73. PubMed ID: 3804520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
    Horai Y; Ishizaki T; Sasaki T; Chiba K; Suganuma T; Echizen H; Ohnishi A
    Eur J Clin Pharmacol; 1983; 24(1):79-87. PubMed ID: 6832206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bioavailability of theophylline in a new oral sustained-release preparation (author's transl)].
    Schneider GF; Heese GU; Huber HJ; Janzen N; Jünger H; Moser C; Stanislaus F
    Arzneimittelforschung; 1981; 31(9):1489-97. PubMed ID: 7197962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption of sustained-release theophylline tablets.
    Fagerström PO; Heintz L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of sustained-release theophylline formulations.
    Bonora Regazzi M; Rondanelli R; Vidale E; Cristiani D
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):245-51. PubMed ID: 6862729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis.
    Valet SB; Schwartz RH; Brooks JG
    Ann Allergy; 1983 Mar; 50(3):161-5. PubMed ID: 6829982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the absorption from some commercial sustained-release theophylline products.
    Upton RA; Thiercelin JF; Guentert TW; Sansom L; Powell JR; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):131-49. PubMed ID: 7431219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Theophylline bioavailability following oral administration of six sustained-release preparations.
    Spangler DL; Kalof DD; Bloom FL; Wittig HJ
    Ann Allergy; 1978 Jan; 40(1):6-11. PubMed ID: 623398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronopharmacokinetics of theophylline after sustained release and intravenous administration to adults.
    Jonkman JH; van der Boon WJ; Balant LP; Schoenmaker R; Holtkamp A
    Eur J Clin Pharmacol; 1984; 26(2):215-22. PubMed ID: 6723760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The bioavailability of 4 sustained-release theophylline preparations from the Chilean market].
    Biagini L; Zamora P; Chávez H; Saavedra I
    Rev Med Chil; 1990 Nov; 118(11):1241-6. PubMed ID: 2152650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.